FDA Cites ibeautistore.com in 2026-04-24 Warning Letter — Unapproved New Drug/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drug/Misbranded
TL;DR
Here's the summary: FDA issued a Warning Letter to ibeautistore.com on 2026-04-24 citing: Unapproved New Drug/Misbranded. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ibeautistorecom-726302-04242026
Argus analysis
ibeautistore.com (MARCS-CMS 726302) received an FDA Warning Letter dated April 24, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: Unapproved New Drug/Misbranded. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 5, 2026.
Unapproved-drug letters cite 21 USC 355 (new drug application requirement) or 21 USC 331(d) (introducing an unapproved new drug into interstate commerce). FDA has increasingly applied these provisions to online sellers of homeopathic products, topical anesthetics, and supplement-adjacent SKUs making unapproved drug claims.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same unapproved new drug category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER ibeautistore.com MARCS-CMS 726302 — April 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Drugs Recipient: ibeautistore.com 3042 Route 22 #38 Dover Plains , NY 12522-5920 United States support@ibeautistore.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER April 24, 2026 RE: 726302 To ibeautistore.com: This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://ibeautistore.com/ in March 2026. The FDA has observed that your website offers “New Hyaluronic Acid 850 mg Sealed 30 Caps” for sale in the United States. In addition, FDA obtained a sample of “New Hyaluronic Acid 850 mg Sealed 30 Caps” through your website, https://ibeautistore.com/. The samples of your “New Hyaluronic Acid 850 mg Sealed 30 Caps” product were labeled as “Umary.” As such, this product will be hereinafter referred to as “Umary.” 1 Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). Furthermore, your “Umary” product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352, and introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a). FDA confirmed through laboratory analysis that a sample of your “Umary” product contains the undeclared active pharmaceutical ingredients diclofenac, dexamethasone, and omeprazole. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. Diclofenac may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland. Abrupt discontinuation can cause withdrawal symptoms. In addition, the undeclared dexamethasone in “Umary” may cause serious side effects when combined with other medications. Omeprazole is a proton pump inhibitor (commonly referred to as PPI) used to treat gastric (stomach) acid-related disorders. PPI medicines may cause serious skin reactions, abdominal pain, diarrhea, nausea, and headache. Omeprazole may mask stomach issues such as…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to ibeautistore.com?
- FDA issued the letter (MARCS-CMS 726302) on 2026-04-24 and posted it publicly on fda.gov on 2026-05-05.
- Is the FDA warning letter to ibeautistore.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ibeautistorecom-726302-04242026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites ibeautistore.com in 2026-04-24 Warning Letter — Unapproved New Drug/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-ibeautistore-com-2026-04-24-unapproved-drug
"FDA Cites ibeautistore.com in 2026-04-24 Warning Letter — Unapproved New Drug/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-ibeautistore-com-2026-04-24-unapproved-drug.
Argus HQ Research. "FDA Cites ibeautistore.com in 2026-04-24 Warning Letter — Unapproved New Drug/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-ibeautistore-com-2026-04-24-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_ibeautistore_com_2026_04_24_unapproved_drug_2026,
title = {FDA Cites ibeautistore.com in 2026-04-24 Warning Letter — Unapproved New Drug/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-ibeautistore-com-2026-04-24-unapproved-drug},
note = {Accessed: July 13, 2026}
}